Amarantus BioScience (AMBS) 10-Q 19 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	15-May-15
Document Information [Line Items]
Entity Registrant Name	Amarantus Bioscience Holdings, Inc.
Entity Central Index Key	1424812
Current Fiscal Year End Date	-19
Entity Filer Category	Smaller Reporting Company
Trading Symbol	AMBS
Entity Common Stock, Shares Outstanding		1,055,960,268
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2015

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$109	$214
Deferred funding fees, net	99	0
Prepaid expenses and other current assets	403	198
Total current assets	611	412
Restricted cash	204	204
Property and equipment, net	165	145
Intangible assets, net	10,277	1,497
Total assets	11,257	2,258
Current liabilities:
Accounts payable and accrued expenses	4,470	3,502
Accounts payable - Regenicin	0	2,550
Related party liabilities and accrued interest	254	252
Accrued interest	54	25
Note Payable	2,850	0
Total current liabilities	7,628	6,329
Total liabilities	7,628	6,329
Stockholders' equity (deficit)
Common stock, $0.001 par value, 2,000,000,000 authorized as of March 31, 2015 and December 31, 2014; 1,012,107,678 and 842,190,750 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively	1,010	842
Additional paid-in capital	57,984	45,050
Accumulated deficit	-62,591	-55,183
Total stockholders' equity (deficit)	3,629	-4,071
Total liabilities and stockholders' equity (deficit)	11,257	2,258
Series A Convertible Preferred Stock [Member]
Stockholders' equity (deficit)
Preferred Stock, Value, Issued	0	0
Series B Convertible Preferred Stock [Member]
Stockholders' equity (deficit)
Preferred Stock, Value, Issued	0	0
Series C Convertible Preferred Stock [Member]
Stockholders' equity (deficit)
Preferred Stock, Value, Issued	1	1
Series D Convertible Preferred Stock [Member]
Stockholders' equity (deficit)
Preferred Stock, Value, Issued	675	1,169
Series E Convertible Preferred Stock [Member]
Stockholders' equity (deficit)
Preferred Stock, Value, Issued	$6,550	$4,050

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Common Stock, Par or Stated Value Per Share (in dollars per share)	$0.00	$0.00
Common Stock, Shares Authorized	2,000,000,000	2,000,000,000
Common Stock, Shares Issued	1,012,107,678	842,190,750
Common Stock, Shares Outstanding	1,012,107,678	842,190,750
Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$0.00	$0.00
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Series A Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$0.00	$0.00
Preferred Stock Shares, Designated	250,000	250,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Series B Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$0.00	$0.00
Preferred Stock Shares, Designated	3,000,000	3,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Series C Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$0.00	$0.00
Preferred Stock Shares, Designated	750,000	750,000
Preferred Stock, Shares Issued	750,000	750,000
Preferred Stock, Shares Outstanding	750,000	750,000
Series D Convertible Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$1,000	$1,000
Preferred Stock Shares, Designated	1,300	1,300
Preferred Stock, Shares Issued	750	1,299
Preferred Stock, Shares Outstanding	750	1,299
Preferred Stock, Liquidation Preference, Value	$750	$750
Series E Convertible Prefered Stock [Member]
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$1,000	$1,000
Preferred Stock Shares, Designated	7,779	7,779
Preferred Stock, Shares Issued	7,277	4,500
Preferred Stock, Shares Outstanding	7,277	4,500
Preferred Stock, Liquidation Preference, Value	$7,277	$7,277

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net sales	$0	$0
Operating expense:
Research and development	2,477	517
General and administrative	4,061	1,119
Total operating expense	6,538	1,636
Loss from operations	-6,538	-1,636
Other income (expense):
Interest expense	-42	-638
Loss on issuance of common stock	0	-67
Loss on issuance of warrants	0	-3,867
Change in fair value of warrants and derivative liabilities	0	666
Total other income (expense)	-42	-3,906
Net loss	-6,580	-5,542
Preferred stock dividends	828	26
Net loss applicable to common shareholders	($7,408)	($5,568)
Basic and diluted net loss per common share (in dollars per share)	($0.01)	($0.01)
Basic and diluted weighted average common shares outstanding (in shares)	1,084,768,816	630,720,618

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $)	Total	Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
In Thousands, except Share data
Balances at Dec. 31, 2014	($4,071)	$5,220	$842	$45,050	($55,183)
Balances (in shares) at Dec. 31, 2014		755,799	842,190,750
Common stock issued for services	106	0	1	105	0
Common stock issued for services (in shares)		0	1,354,269
Stock-based compensation expense	488	0	0	488	0
Common stock sold	2,819	0	38	2,781	0
Common stock sold (in shares)			38,445,801
Common stock issued for funding fees	0	0	1	-1	0
Common stock issued for funding fees (in shares)			493,436
Common stock issued for acquisition of DioGenix	7,950	0	99	7,851	0
Common stock issued for acquisition of DioGenix (in shares)			99,378,881
Sale of Series E Preferred Stock	2,950	2,950	0	0	0
Sale of Series E Preferred Stock (in shares)		3,278
Common stock issued for Series D convertible preferred stock dividend	26	0	1	34	-9
Common stock issued for Series D convertible preferred stock dividend (in shares)			1,172,911
Common stock issued for Series E convertible preferred stock dividend	65	0	3	234	-172
Common stock issued for Series E convertible preferred stock dividend (in shares)			3,260,730
Series E accretion of beneficial conversion feature as deemed dividend	0	0	0	440	-440
Series D stock conversion	0	-494	18	476	0
Series D stock conversion (in shares)		-549	18,310,900
Series E stock conversion	0	-450	6	444	0
Series E stock conversion (in shares)		-500	6,250,000
Common Stock issued as fee for debt financing arrangement	102	0	1	101	0
Common Stock issued as fee for debt financing arrangement (in shares)			1,250,000
Legal fees related to stock offering	-19	0	0	-19	0
Series D dividend accrued	-15	0	0	0	-15
Series E dividend accrued	-192	0	0	0	-192
Net loss	-6,580	0	0	0	-6,580
Balances at Mar. 31, 2015	$3,629	$7,226	$1,010	$57,984	($62,591)
Balances (in shares) at Mar. 31, 2015		758,028	1,012,107,678

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities
Net loss	($6,580)	($5,542)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	19	1
Amortization of debt discount	0	500
Amortization of deferred financing fees	0	96
Amortization of intangible assets	32	24
Stock issued for services	106	184
Non cash financing expense	14	0
Loss on stock issuance	0	67
Loss on warrant issuance	0	3,867
Non-cash interest expense related to warrants and derivative	0	32
Change in fair value of warrants and derivative liability	0	-666
Stock-based compensation expense	488	202
Changes in assets and liabilities:
Related party liabilities and accrued interest	0	1
Clinical trial material	0	-500
Prepaid expenses and other current assets	-62	-25
Accounts payable and accrued expenses	-1,851	560
Accrued interest	29	-60
Net cash used in operating activities	-7,805	-1,259
Cash flows from investing activities
Acquisition of DioGenix	-900	0
Acquisition of other assets	0	-500
Acquisition of property and equipment	-1	-9
Net cash used by investing activities	-901	-509
Cash flows from financing activities
Proceeds from borrowings	2,850	500
Financing Costs	-19	0
Proceeds from issuance of common stock	2,820	400
Proceeds from exercise of warrants	0	3,600
Proceeds from issuance of convertible preferred stock	2,950	0
Net cash provided by financing activities	8,601	4,500
Net increase in cash and cash equivalents	-105	2,732
Beginning of period	214	1,033
End of period	109	3,765
Supplemental schedule of non-cash activities:
Convertible debentures converted and associated reclassification of derivative liabilities	0	7,778
Debt discount written off - associated with convertible promissory notes	0	-1,740
Stock issued for deferred funding fees	0	516
Common stock issued as fee for debt financing arrangement	102	0
Convertible Debt [Member]
Supplemental schedule of non-cash activities:
Stock Issued	0	11
Series D Preferred Dividend [Member]
Supplemental schedule of non-cash activities:
Series preferred stock dividend accrued	-15	0
Series E Preferred Dividend [Member]
Supplemental schedule of non-cash activities:
Series preferred stock dividend accrued	-192	0
Common Stock [Member]
Cash flows from operating activities
Net loss	0
Common Stock Issued For Series D Preferred Stock [Member]
Supplemental schedule of non-cash activities:
Stock Issued	35	0
Conversion of Stock, Amount Issued	-9	0
Common Stock Issued For Series E Preferred Stock [Member]
Supplemental schedule of non-cash activities:
Stock Issued	237	0
Conversion of Stock, Amount Issued	($172)	$0

GENERAL

GENERAL	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature Of Operations [Text Block]
		1	GENERAL
	Amarantus Bioscience Holdings, Inc. (the “Company”), is a biopharmaceutical company focused on the development of diagnostics and therapeutics to treat human disease, to date primarily in for Alzheimer's disease, Parkinson's disease and ophthalmological disorders. Through March 31, 2015, the Company has been primarily engaged in acquiring and licensing intellectual property and proprietary technologies, research and development, and raising capital to fund its operations.
	Amarantus Bioscience has three operating divisions: the diagnostics division; the therapeutics division; and the other drug discovery division.
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.  All significant intercompany balances and transactions have been eliminated in consolidation.
	The unaudited condensed consolidated financial statements (Financial Statements) have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments (consisting of normal recurring adjustments unless otherwise indicated) which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Certain prior year amounts have been reclassified to conform to current year presentation.
	Certain information in footnote disclosures normally included in the financial statements prepared in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to the SEC rules and regulations for interim reporting. The financial results for the periods presented may not be indicative of the full year’s results. The Company believes the disclosures are adequate to make the information presented not misleading.
	These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the fiscal year ended December 31, 2014 included in the Company’s Annual Report on Form 10K filed in April 2015.
	Significant Accounting Policies
	Accounting for Business Combinations
	Business combinations are accounted for under the acquisition method of accounting. This method requires the recording of acquired assets, including separately identifiable intangible assets, and assumed liabilities at their acquisition date fair values. The method records any excess purchase price over the fair value of acquired net assets as goodwill. The determination of the fair value of assets acquired, liabilities assumed involves assessments of factors such as the expected future cash flows associated with individual assets and liabilities and appropriate discount rates at the closing date of the acquisition. When necessary, external advisors are consulted to help determine fair value. For non-observable market values, fair values are determined using acceptable valuation principles (e.g., multiple excess earnings, relief from royalty and cost methods, discounted cash flows).
	Contingent consideration assumed in a business combination is remeasured at fair value each reporting period and any change in the fair value from either the passage of time or events occurring after the acquisition date, is recorded in results from operations.
	The results of operations are included from the acquisition date in the financial statements for all businesses acquired.
	Goodwill and Other Identifiable Intangibles
	Goodwill and indefinite-lived intangibles are reviewed annually for impairment. When testing goodwill and indefinite-lived intangibles for impairment, we first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (more than 50%) that an impairment exists. Such qualitative factors may include the following: macroeconomic conditions; industry and market considerations; cost factors; overall financial performance; and other relevant entity-specific events. In the event the qualitative assessment indicates that an impairment is more likely than not, we would be required to perform a quantitative impairment test, otherwise no further analysis is required.
	Under the quantitative goodwill impairment test, the evaluation of impairment involves comparing the current fair value (using Level 3 inputs) of each reporting unit to its carrying value, including goodwill.
	If the carrying amount of a reporting unit, including goodwill, exceeds the estimated fair value, then individual assets (including identifiable intangible assets) and liabilities of the reporting unit are estimated at fair value. The excess of the estimated fair value of the reporting unit over the estimated fair value of its net assets would establish the implied value of goodwill. The excess of the recorded amount of goodwill over the implied value is then charged to earnings as an impairment loss.
	In-process research & development ("IPR&D") represents the fair value assigned to research and development assets that were not fully developed at the date of acquisition. IPR&D acquired in a business combination is capitalized on the Company's consolidated balance sheet at its acquisition-date fair value. Until the project is completed, the assets are accounted for as indefinite-lived intangible assets and subject to impairment testing. Upon completion of a project, the carrying value of the related IPR&D is reclassified to intangible assets and is amortized over the estimated useful life of the asset.
	When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its acquired IPR&D. If the Company determines, as a result of the qualitative assessment, that it is more likely than not that the fair value of acquired IPR&D is less than its carrying amount, it calculates the asset's fair value. If the carrying value of the Company's acquired IPR&D exceeds its fair value, then the intangible asset is written down to its fair value.
	Recently Issued Accounting Pronouncements
	In April 2015, the Financial Accounting Standards Board issued a new pronouncement that requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. The pronouncement becomes effective for the Company in the first quarter of 2016. Early adoption is permitted. The Company believes adoption of the pronouncement will not have a significant impact on the financial statements or its results of operations.

LIQUIDITY_AND_GOING_CONCERN

LIQUIDITY AND GOING CONCERN	3 Months Ended
	Mar. 31, 2015
Liquidity And Going Concern [Abstract]
Liquidity And Going Concern [Text Block]		2	LIQUIDITY AND GOING CONCERN
	The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings. Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably. Our activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. Historically, we have incurred net losses and negative cash flows from operations.
	The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.
	The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”), which contemplate continuation of the Company as a going concern. As of March 31, 2015, the Company had cash and cash equivalents of $109. On April 23, 2015, we entered into a Stock Purchase Agreement (“SPA”) with Discover Growth Fund, a Cayman Islands exempted mutual fund (“Discover”), pursuant to which the we sold and issued 1,087 shares of our newly designated Series G Preferred Stock (“Series G Preferred Stock”) for gross proceeds of $5,000 and an 8% original issue discount. Historically, the Company has incurred net losses and negative cash flows from operations. The Company believes its current capital resources are not sufficient to support its operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.

ACQUISITION

ACQUISITION	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	3	ACQUISITION
	On January 8, 2015, the Company, through a wholly-owned subsidiary, entered into an agreement and plan of merger (the “Merger”) for the acquisition of all of the outstanding stock of DioGenix, Inc. The Company acquired DioGenix for its pipeline of diagnostic tests focused on immune-mediated neurological diseases, such as multiple sclerosis (MS). Its lead product, MSPrecise, can significantly expand a physician's ability to diagnose patients that exhibit unclear neurological dysfunction.
	The transaction closed on January 9, 2015 with DioGenix, Inc. surviving the Merger and becoming a wholly-owned subsidiary of the Company. Consideration paid included 99,378,881 shares of Company stock valued at $0.08 per share and $900 in cash for a total consideration of $8,850. In addition, the agreement provides for a contingent payment amount up to $2,000 in cash and common stock of the Company should the acquired company achieve certain milestones related to results of clinical testing and future revenue from products in development. The fair value of the contingent consideration was estimated by applying the income approach. That measure is based on significant inputs that are not observable in the market (Level 3 inputs). Key assumptions include the discount rate of 30.4% and probability-adjusted potential outcomes.
	Following an acquisition, there is a period of not more than twelve months from the closing date of the acquisition to finalize the acquisition date fair values of assets acquired and liabilities assumed, including valuations of identifiable intangible assets and property and equipment. The determination of fair values of acquired intangible assets and property and equipment involves a variety of assumptions, including estimates associated with remaining useful lives.
	The preliminary purchase price adjustments of the assets and liabilities acquired in the January 9, 2015 Merger is $8,867.
	We incurred acquisition costs of $169 which were expensed.
	The following unaudited supplemental pro forma information presents the financial results as if the Merger had occurred on January 1, 2014. This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2014, nor is it indicative of any future results.
			Three months ended
			March 31, 2014
	Net Sales		$	—
	Operating Expenses			2,229
	Loss from operations		$	-2,229
	Total other (expenses)			-4,023
	Net loss		$	-6,252
	Basic and diluted net loss per common share		$	-0.01
	Basic and diluted weighted average common shares outstanding			630,720,618
	Condensed Consolidated Statement of Operations shows a consolidated net loss of $6,580 for the first quarter of 2015 and included the results of DioGenix after the merger on January 9, 2015. The loss incurred during the first eight days of January 2015 is immaterial for comparison purposes.

NET_LOSS_PER_SHARE

NET LOSS PER SHARE	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	4	Net loss per share
	The following table sets forth the computation of the basic and diluted net loss per share attributable to Amarantus common stockholders for the periods indicated:
			Three Months Ended
			March 31,
			2015		2014
	Numerator
	Net loss		$	-6,580	$	-5,542
	Preferred stock dividend			828		26
	Net loss applicable to common stockholders		$	-7,408	$	-5,568
	Denominator
	Common stock - basic			959,737,290		630,720,618
	Common shares equivalents(1)			125,031,526		—
	Weighted average shares outstanding during the period:			1,084,768,816		630,720,618
	Net loss per share		$	-0.01	$	-0.01
	(1) Preferred Stock Series D and E are participating securities; therefore we utilize the two class method of computing net loss per share.
	Potentially dilutive securities:
	Outstanding common stock options(2)			56,916,000		18,296,000
	Outstanding preferred stock option(2)			2,488,000		2,488,000
	Warrants(2)			45,861,000		69,553,000
	Related party liability(2)			5,070,000		3,214,000
	Convertible promissory note(s)(2)			—		5,655,000
	8% Senior convertible debentures			—		8,776,000
	Convertible preferred stock(2)			750,000		750,000
		-2	The impact of stock options, warrants, convertible debt instruments and convertible preferred stock that does not have participation rights is anti-dilutive in a period of loss from continuing operations.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]		5	intangible assets
	The following table summarizes our intangible assets:
			Period Ended
			March 31,		December 31,
			2015		2014
	Intangibles - Acquisition Diogenix (Preliminary IPRD)		$	8,812	$	—
	Licenses			1,685		1,685
	Accumulated amortization of licenses			-220		-188
	Total licenses net			1,465		1,497
	Total intangible assets		$	10,277	$	1,497
	These license costs will be amortized over the expected remaining lives of the respective patents. As of March 31, 2015, amortization expense for the next five years is expected to be as follows:
	2015 (remaining nine months)		$	96
	2016			128
	2017			128
	2018			128
	2019			128
	thereafter			857
	Total		$	1,465

DEMAND_PROMISSORY_NOTE

DEMAND PROMISSORY NOTE	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]		6	DEMAND PROMISSORY NOTE
	On February 23, 2015, the Company entered into a Securities Purchase Agreement with Dominion Capital pursuant to which the Company issued a 12% Promissory Note (the “February Note”) in the principal amount of $2,500 due and payable on December 23, 2015 in cash or stock or a combination at the Company’s option. At any time upon ten (10) days written notice to Dominion Capital, the Company may prepay any portion of the principal amount of the February Note and any accrued and unpaid interest at an amount equal to 110% of the then outstanding principal amount of the February Note and guaranteed interest, 10% of which may be paid in cash or, at the Company’s option, in common stock or a combination thereof.
	The February Note contains certain customary Events of Default (including, but not limited to, default in payment of principal or interest thereunder, breaches of covenants, agreements, representations or warranties thereunder, the occurrence of an event of default under certain material contracts of the Company, including the transaction documents relating to the Note transaction, changes in control of the Company and the entering or filing of certain monetary judgments against the Company). Upon the occurrence of any such Event of Default the outstanding principal amount of the February Note, plus accrued but unpaid interest, liquidated damages, and other amounts owing in respect thereof through the date of acceleration, shall become, at the Investor’s election, immediately due and payable in cash. Upon any Event of Default that results in acceleration of the February Note, the interest rate on the Note shall accrue at an interest rate equal to the lesser of 24% per annum or the maximum rate permitted under state law at the time of the default.
	In connection with the February Note Transaction, effective on February 23, 2015, the Company entered into a Security Agreement with the Investor (the “Security Agreement”) pursuant to which the Company granted a security interest in certain of its property (the “Collateral”) to Dominion Capital in order to secure the prompt payment, performance and discharge in full of all of the Company’s obligations under the Note. The Collateral shall consist of all of the Company’s rights, title and interest in and to that certain Asset Purchase Agreement, dated November 7, 2014, by and among the Company, Regenicin, Inc., Clark Corporate Law Group, LLP, and Gordon & Rees, LLP and that certain Option Agreement, dated November 7, 2014, by and between the Company and Lonza Walkersville.
	As part of the financing, Dominion received 1,250,000 shares of the Company’s restricted common stock valued at $102 and recorded as deferred financing on the balance sheet and will be amortized over the term of the loan.
	On March 31, 2015, the Company issued an additional Note to Dominion in the principal amount of $350. The March Note was issued upon the same terms and conditions as the February Note.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]		7	commitments and contingencies
	Commitments:
	Sponsored Research Arrangements:
	We entered into a number of sponsored research agreements during 2014, primarily, which require us to make future payments as follows:
	2015 (remaining)		$	239
	2016			150
	Total		$	389
	Research, License, and Option to License Arrangements
	The Company is a party to various agreements which obligate it to make certain payments:
	Acquiring Engineered Skin Substitute Intellectual Property - Lonza Walkersville
	On March 27, 2015, the Company entered into a third amendment to the Lonza Option Agreement that further extended the Option period from March 31, 2015 to August 31, 2015, on a month-by-month basis. In connection with this third amendment, the Company will make additional periodic payments to Lonza, a portion of which will fund Lonza’s continuing Engineering Skin Substitute (“ESS”) development activity. Upon execution of this third amendment, the Company paid $350 to Lonza on March 31, 2015 and will pay the following additional amounts to Lonza until the earlier of such time as the Option is exercised or August 31, 2015:
		·	$400 on April 30, 2015 for the option period of April 1, 2015 to April 30, 2015,
		·	$600 on May 31, 2015 for the option period of May 1, 2015 to May 31, 2015,
		·	$600 on June 30, 2015 for the option period of June 1, 2015 to June 30, 2015 and
		·	$600 on July 31, 2015 for the option period of July 1, 2015 to July 31 2015
	If the Company exercises the Option and consummates the SPA prior to any option payment being due, then no further payment(s) shall be required. In the event the SPA is not consummated, then the Company will incur a $1,000 break-up fee payable to Lonza.
	Regenicin Asset Purchase Agreement
	The second step in the acquisition of ESS required the Company to enter into an Asset Purchase Agreement (the “Regenicin APA”) with Regenicin, Inc. (“Regenicin”) and other interested parties under which the Company agreed to acquire certain assets of Regenicin (the “Assets”), including (i) rights to a lawsuit that Regenicin brought against Lonza (the “Litigation”), and (ii) all intellectual property rights held by Regenicin related to any engineered skin technology for the treatment of severe burns in humans, including any related trademarks. The Regenicin APA was executed October 27, 2014. As consideration to Regenicin, the Company agreed to pay to Regenicin a total of $3,600 and 37,500,000 shares of Amarantus common stock. The shares were issued to Regenicin in November 2014 (valued at approximately $3,000), along with cash payments of $1,100. The remaining cash payments of $2,500 due to Regenicin under the Regenicin APA were paid by the end of February 2015. The asset purchase was recorded at its fair value as in-process research and development expense in the statement of operations.
	Compensatory Arrangements of Certain Officers:
	Gerald E. Commissiong:
	Effective October 6, 2014, the Company entered into an employment letter with Gerald E. Commissiong pursuant to the employment letter Mr. Commissiong will continue to serve as the Company’s President and Chief Executive Officer.
	Pursuant to the Employment Letter, Mr. Commissiong shall be entitled to an initial base salary (“Base Salary”) of $225 per year, which shall automatically increase to $338 per year upon the Company becoming listed on the NASDAQ Stock Market. In addition to the Base Salary, Mr. Commisiong shall be eligible for a performance bonus of up to 35% of his Base Salary, which shall be based upon certain milestones set by the Company’s Board of Directors in their sole discretion. The Employment Letter provides for the payment of a signing bonus of $50, which was paid in 2014.
	In addition, pursuant to the Employment Letter, the Company granted Mr. Commissiong stock options to purchase five million (5,000,000) shares of the Company’s common stock at a per share price equal to fair market value on the date of the grant, subject to a four year vesting schedule as described in the Employment Letter.
	Mr. Commissiong’s employment with the Company will be “at will”. Should Mr. Commissiong’s employment with the Company be terminated by the Company for a reason other than for “Cause” (as defined in the Employment Letter) or Mr. Commissiong terminates his employment with the Company for “Good Reason” (as defined in the Employment Letter), Mr. Commissiong shall, upon execution of a release agreement with the Company, be entitled to receive as severance: (i) one year of his then Base Salary to be paid in the form of monthly salary continuation, (ii) one year of continued coverage under the Company’s health care benefit package, (iii) a full performance bonus equal to 35% of his then Base Salary, and (iv) immediate acceleration of 25% of all outstanding unvested equity awards then held by Mr. Commissiong.
	Should Mr. Commissiong’s employment with the Company be terminated by the Company for a reason other than for “Cause” or Mr. Commissiong terminates his employment with the Company for “Good Reason” in connection with or during the twelve (12) month period immediately following the effective date of a “Change in Control” (as defined in the Employment Letter), and provided such termination constitutes a “separation from service” as that term is defined pursuant to the Treasury Regulation Section 1-409A-1(h), in addition to the severance package as described above, Mr. Commissiong shall be entitled to have all outstanding unvested equity awards then held by Mr. Commissiong become fully vested and, if applicable, exercisable.
	John W. Commissiong, PhD:
	Effective December 31, 2014 the Company entered into an employment letter with John W. Commissiong, PhD, pursuant to the employment letter Dr. Commissiong will continue to serve as the Company’s Chief Scientific Officer, with an initial term of one year. After the initial term Dr. Commissiong’s employment with the Company shall be on an “at will” basis.
	Dr. Commissiong’s initial annual base salary shall be $175 per year, upon the Company’s “up-listing” to a National Listing, his annual Base Salary will immediately be increased to $266. Mr. Commissiong also will receive the Company’s standard employee benefits.
	Additionally, Dr. Commissiong will be eligible to earn a discretionary Performance Bonus of up to 30% of his base salary. This Performance Bonus is conditioned upon satisfaction, in the Company’s sole discretion, of the Performance Bonus Conditions to be proposed by the CEO and agreed with the Company Compensation Committee.
	The Company also provided Dr. Commissiong you with a Signing Bonus of $10, less standard deductions and withholdings, within ten (10) days of execution of the Employment Agreement.
	In addition, the Company will grant Dr. Commissiong a stock option to purchase 3,500,000 shares of the Company’s Common Stock at a price per share equal to the fair market value per share of the Common Stock on the date of grant, as determined by the Company’s Board of Directors.

EQUITY

EQUITY	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	8	Equity
	Private Placement of Common Stock
	During the first quarter of 2015 under the Lincoln Park Capital Fund LLC financing arrangement the Company sold 38,445,801 common shares and issued 493,436 common shares as a commitment fee for a total of $2,819. $14,506 funding remains available under the financing arrangement as of March 31, 2015.
	Series D Preferred Stock
	During the first quarter of 2015, 549 shares of Series D preferred stock were converted to 18,310,900 common shares, and 306,693 shares of common stock were issued as a dividend due upon conversion.
	Subsequent to March 31, 2015, 400 shares of Series D preferred stock were converted to 13,333,332 common shares.
	Series E Preferred Stock
	During the first quarter of 2015, 3,278 shares of Series E preferred stock were sold for $2,950. Also during the first quarter of 2015, 500 shares of Series E preferred stock were converted to 6,250,000 common shares, and 2,375,204 shares of common stock were issued as a dividend due upon conversion.
	On April 2, 2015 the company amended the Series E preferred Stock Certificate of Designation for the following:
		·	Increased the number of authorized shares from 7,779 to 13,335.
		·	Reduced the conversion price from $0.08 to $0.05.
		·	Issued 30,000,000 Company restricted common shares to existing investors as of April 2, 2015.
	Subsequent to March 31, 2015 the Company issued 444 shares of Series E preferred stock for $360.

STOCK_OPTION_PLANS

STOCK OPTION PLANS	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]		9	STOCK OPTION PLANS
	2008 Stock Plan
	The Company’s Board of Directors approved the 2008 Stock Plan (the “Plan”). Under the Plan, the Company may grant up to 46,119,832 shares of incentive stock options, nonqualified stock options, or stock awards to eligible persons, including employees, nonemployees, members of the Board of Directors, consultants, and other independent advisors who provide services to the Company. In general, options are granted with an exercise price equal to the fair value of the underlying common stock on the date of the grant. Options granted typically have a contractual life of 10 years and vest over periods ranging from being fully vested as of the grant date to four years.
	The following table is a summary of activity under the 2008 Plan:
			Common Stock Options Outstanding			Weighted Average Exercise Price			Weighted Average Remaining Contractual		Aggregate Intrinsic Value
									Term  (Years)		$0
	Balance December 31, 2014			21,596,127		$	0.08			8.8	$	47
	Options granted (weighted-average fair value of $0.08)
	Employee (1)			—			—			—
	Non-employee			—			—			—
	Options cancelled			-1,500,000			0.1			—
	Options exercised			—			—			—
	Balance March 31, 2015			20,096,127		$	0.08			8.6	$	17
	Options vested as of March 31, 2015			15,035,635
	2012 Preferred Stock Plan
	In July 2012, our Board of Directors adopted a new stock plan, the Management, Employee, Advisor and Director Preferred Stock Option Plan – 2012 Series B Convertible Preferred Stock Plan (“Preferred Stock Plan”). The purposes of the Preferred Stock Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Management, Employees, Advisors and Directors and to promote the success of our business. These options currently vest over two or three years and cannot be converted into common shares or sold for two years from the date of the Designation of the Series B Preferred shares. Each share of Series B Preferred stock converts into fifty shares of common stock.
	The following table is a summary of activity under the Preferred Stock Plan:
			Preferred Stock			Weighted Average			Weighted		Aggregate
			Options			Exercise Price			Average		Intrinsic
			Outstanding						Remaining		Value
									Contractual		$0
									Term
									(Years)
	Balance – December 31, 2014			2,487,500		$	0.61			8.1	$	6,836
	Preferred options cancelled			—			—			—
	Preferred options granted (weighted-average fair value of $1.61)
	Employee			—			—			—
	Non-Employee			—			—			—
	Balance – March 31, 2015			2,487,500		$	0.61			7.6	$	4,714
	Preferred options vested as of March 31, 2015			2,154,036
	2014 Stock Plan
	In August 2014, the Company adopted the 2014 Stock Plan (the “2014 Plan”), which was approved by the Company’s stockholder at the Company’s Annual Meeting in September 2014. Under the 2014 Plan, the Company may grant up to 153,880,168 common shares in the form of incentive stock options, nonqualified stock options or stock awards to eligible persons, including employees, nonemployees, members of the Board of Directors, consultants, and other independent advisors who provide services to the Company. In general, options are granted with an exercise price equal to the fair value of the underlying common stock on the date of the grant. Options granted typically have a contractual life of 10 years and vest over periods ranging from being fully vested as of the grant date to four years.
	The following table is a summary of activity under the 2014 Plan:
			Common Stock			Weighted Average Exercise Price			Weighted Average Remaining
			Options						Contractual Term  (years)
			Outstanding
	Balance – December 31, 2014			8,600,000		$	0.09			9.8
	Options granted (weighted-average fair value of $0.08)
	Employee			24,970,000			0.08			9.1
	Non-Employee			2,250,000			0.08			0.8
	Options cancelled			—			—			—
	Options Exercised			—			—			—
	Balance March 31, 2015			35,820,000		$	0.08			9.7
	Options vested as of March 31, 2015			4,816,181
	Stock-based compensation expense for all plans is classified in the statements of operations as follows:
			Three Months Ended March 31,
			2015			2014
	Research and development		$	184		$	78
	General and administrative			304			124
	Total		$	488		$	202
	At March 31, 2015, there was a total of approximately $3,089 of unrecognized compensation cost, related to non-vested stock option awards, which is expected to be recognized over a weighted-average period of approximately 2.9 years. The Company has estimated a forfeiture rate of 0% due to a low history of forfeitures and the majority of grants being held by senior level executives.
	The fair value of the Company’s stock-based awards during the three months ended March 31, 2015 and 2014 were estimated using the Black-Scholes option-pricing model with the following assumptions:
				Three Months Ended March 31,
				2015			2014
	Weighted-average volatility			262	%		89.2	%
	Weighted-average expected term			9.98			5
	Expected dividends			0	%		0	%
	Risk-free investment rate			1.65	%		1.65	%

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]		10	SUBSEQUENT EVENTS
	Series G Preferred Stock
	On April 23, 2015, the Company, entered into a Stock Purchase Agreement (“SPA”) with Discover Growth Fund, a Cayman Islands exempted mutual fund (“Discover”), pursuant to which the Company sold and issued 1,087 shares of the Company’s newly designated Series G Preferred Stock (“Series G Preferred Stock”) for gross proceeds of $5,000 and an 8% original issue discount. On April 23, 2015, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of the Series G Preferred Stock (“Certificate of Designation”) with the Secretary of State of the State of Nevada.
	Holders of the Series G Preferred Stock are entitled to cumulative dividends in the amount of 8.25% per annum, payable upon redemption or upon conversion and when, as and if declared by the Board of Directors in its discretion. Dividends are payable through the sixth anniversary of the issuance date. On the sixth anniversary of the issuance date, all remaining outstanding shares of Series G Preferred Stock will automatically be converted into shares of common stock.
	The Series G Preferred Stock is convertible into shares of the Company’s common stock at a fixed conversion price of $0.06 per share of common stock. The Series G Preferred Stock may be converted into shares of common stock at any time at the option of the holder. The Series G Preferred Stock may also be converted into shares of common stock at the option of the Company if the Equity Conditions, as defined in the Certificate of Designation, are met. Upon conversion, the Company shall pay the holders of the Series G Preferred Stock being converted a conversion premium equal to the amount of dividends that such shares would have otherwise earned if they had been held through the maturity date, and issue to the Investor such number of shares of common stock equal to $5,000 per share of Series G Preferred Stock (the “Face Value”) multiplied by the number of Series G Preferred Stock divided by the conversion rate of $0.06.
	The conversion premium may be paid in cash or, at the Company’s option, additional shares of common stock. If the Company elects to pay the conversion premium amount in the form of common stock the number of shares to be issued shall be calculated by using 80% of the average of the lowest 5 individual daily volume weighted average prices during the measuring period, not to exceed 100% of the lowest sales prices on the last day of such period, less $0.005 per share of common stock. Under certain circumstances, the number of shares to be issued shall be calculated by using 65% of the average of the lowest 5 individual daily volume weighted average prices during the measuring, less $0.005 per share of common stock not to exceed 70% of the lowest sales prices on the last day of such period less $0.005 per share. The Certificate of Designations describes these circumstances which include, but are not limited to, the breach of any covenant or representation in the SPA, the Certificate of Designations or any other transaction documents, and the suspension of trading of the Company’s common stock on its principal trading market.
	The dividend rate on the Series G Preferred Stock shall adjust upward by 150 basis points for each $0.0025 that the volume weighted average price of the Company’s common stock on any trading day as of which the dividend rate is determined and calculated is below $0.045, subject to a maximum dividend rate of 24%. The dividend rate on the Series G Preferred Stock shall adjust downward by 150 basis points for each $0.0025 that the volume weighted average price of our common stock on any trading day as of which the dividend rate is determined and calculated is above $0.08, subject to a minimum dividend rate of 0%.
	The Company will have the right, at its option, to redeem for cash all or a portion of the Series G Preferred Stock at a price 100% of the Face Value plus the conversion premium less any period for which dividends have previously been paid with respect to the Series G Preferred Stock being redeemed. Upon the listing of the Company’s common stock on a senior exchange, the Company may redeem the outstanding Series G Preferred Stock at 120% of the Face Value.
	Upon the liquidation, dissolution or winding up, holders of Series G Preferred Stock will be entitled to be paid out of the Company’s assets, on parity with holders of our common stock and our Preferred Stock, an amount equal to $5,000 per share plus any accrued but unpaid dividends thereon.
	Pursuant to the terms of the SPA, the Company has agreed to include the shares into which the Series G Preferred Stock are convertible in a registration statement on S-3 to be filed on or before May 5, 2015, and to have such registration statement remain effective until all of the Conversion Shares may be resold under Rule 144, without volume or manner restrictions. If the registration statement is not declared effective within 90 days of the closing date of the SPA, the Company shall issue to the investor 22 additional Series G Preferred Stock for each 30 day period until the Conversion Sales may be sold without restriction. The S-3 was filed on May 4, 2015.
	The SPA also provides certain trading restrictions in the event of a reverse split or combination of the Company’s shares of common stock and restrictions on subsequent financings in the six months following the closing date. The SPA also contains shorting restrictions on the Investor.
	The Company is currently evaluating the accounting treatment and disclosures to be implemented in its financial statements and notes for the Series G preferred stock.

GENERAL_Policies

GENERAL (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries.  All significant intercompany balances and transactions have been eliminated in consolidation.
	The unaudited condensed consolidated financial statements (Financial Statements) have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments (consisting of normal recurring adjustments unless otherwise indicated) which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Certain prior year amounts have been reclassified to conform to current year presentation.
	Certain information in footnote disclosures normally included in the financial statements prepared in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to the SEC rules and regulations for interim reporting. The financial results for the periods presented may not be indicative of the full year’s results. The Company believes the disclosures are adequate to make the information presented not misleading.
	These financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the fiscal year ended December 31, 2014 included in the Company’s Annual Report on Form 10K filed in April 2015.
Business Combinations Policy [Policy Text Block]	Accounting for Business Combinations
	Business combinations are accounted for under the acquisition method of accounting. This method requires the recording of acquired assets, including separately identifiable intangible assets, and assumed liabilities at their acquisition date fair values. The method records any excess purchase price over the fair value of acquired net assets as goodwill. The determination of the fair value of assets acquired, liabilities assumed involves assessments of factors such as the expected future cash flows associated with individual assets and liabilities and appropriate discount rates at the closing date of the acquisition. When necessary, external advisors are consulted to help determine fair value. For non-observable market values, fair values are determined using acceptable valuation principles (e.g., multiple excess earnings, relief from royalty and cost methods, discounted cash flows).
	Contingent consideration assumed in a business combination is remeasured at fair value each reporting period and any change in the fair value from either the passage of time or events occurring after the acquisition date, is recorded in results from operations.
	The results of operations are included from the acquisition date in the financial statements for all businesses acquired.
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]	Goodwill and Other Identifiable Intangibles
	Goodwill and indefinite-lived intangibles are reviewed annually for impairment. When testing goodwill and indefinite-lived intangibles for impairment, we first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (more than 50%) that an impairment exists. Such qualitative factors may include the following: macroeconomic conditions; industry and market considerations; cost factors; overall financial performance; and other relevant entity-specific events. In the event the qualitative assessment indicates that an impairment is more likely than not, we would be required to perform a quantitative impairment test, otherwise no further analysis is required.
	Under the quantitative goodwill impairment test, the evaluation of impairment involves comparing the current fair value (using Level 3 inputs) of each reporting unit to its carrying value, including goodwill.
	If the carrying amount of a reporting unit, including goodwill, exceeds the estimated fair value, then individual assets (including identifiable intangible assets) and liabilities of the reporting unit are estimated at fair value. The excess of the estimated fair value of the reporting unit over the estimated fair value of its net assets would establish the implied value of goodwill. The excess of the recorded amount of goodwill over the implied value is then charged to earnings as an impairment loss.
	In-process research & development ("IPR&D") represents the fair value assigned to research and development assets that were not fully developed at the date of acquisition. IPR&D acquired in a business combination is capitalized on the Company's consolidated balance sheet at its acquisition-date fair value. Until the project is completed, the assets are accounted for as indefinite-lived intangible assets and subject to impairment testing. Upon completion of a project, the carrying value of the related IPR&D is reclassified to intangible assets and is amortized over the estimated useful life of the asset.
	When performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its acquired IPR&D. If the Company determines, as a result of the qualitative assessment, that it is more likely than not that the fair value of acquired IPR&D is less than its carrying amount, it calculates the asset's fair value. If the carrying value of the Company's acquired IPR&D exceeds its fair value, then the intangible asset is written down to its fair value.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements
	In April 2015, the Financial Accounting Standards Board issued a new pronouncement that requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability. The pronouncement becomes effective for the Company in the first quarter of 2016. Early adoption is permitted. The Company believes adoption of the pronouncement will not have a significant impact on the financial statements or its results of operations.

ACQUISITION_Tables

ACQUISITION (Tables)	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Business Acquisition, Pro Forma Information [Table Text Block]	This supplemental pro forma information has been prepared for comparative purposes and does not purport to be indicative of what would have occurred had the acquisition been made on January 1, 2014, nor is it indicative of any future results.
		Three months ended
		March 31, 2014
	Net Sales	$	—
	Operating Expenses		2,229
	Loss from operations	$	-2,229
	Total other (expenses)		-4,023
	Net loss	$	-6,252
	Basic and diluted net loss per common share	$	-0.01
	Basic and diluted weighted average common shares outstanding		630,720,618

NET_LOSS_PER_SHARE_Tables

NET LOSS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The following table sets forth the computation of the basic and diluted net loss per share attributable to Amarantus common stockholders for the periods indicated:
			Three Months Ended
			March 31,
			2015		2014
	Numerator
	Net loss		$	-6,580	$	-5,542
	Preferred stock dividend			828		26
	Net loss applicable to common stockholders		$	-7,408	$	-5,568
	Denominator
	Common stock - basic			959,737,290		630,720,618
	Common shares equivalents(1)			125,031,526		—
	Weighted average shares outstanding during the period:			1,084,768,816		630,720,618
	Net loss per share		$	-0.01	$	-0.01
	(1) Preferred Stock Series D and E are participating securities; therefore we utilize the two class method of computing net loss per share.
	Potentially dilutive securities:
	Outstanding common stock options(2)			56,916,000		18,296,000
	Outstanding preferred stock option(2)			2,488,000		2,488,000
	Warrants(2)			45,861,000		69,553,000
	Related party liability(2)			5,070,000		3,214,000
	Convertible promissory note(s)(2)			—		5,655,000
	8% Senior convertible debentures			—		8,776,000
	Convertible preferred stock(2)			750,000		750,000
		-2	The impact of stock options, warrants, convertible debt instruments and convertible preferred stock that does not have participation rights is anti-dilutive in a period of loss from continuing operations.

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	The following table summarizes our intangible assets:
		Period Ended
		March 31,		December 31,
		2015		2014
	Intangibles - Acquisition Diogenix (Preliminary IPRD)	$	8,812	$	—
	Licenses		1,685		1,685
	Accumulated amortization of licenses		-220		-188
	Total licenses net		1,465		1,497
	Total intangible assets	$	10,277	$	1,497
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	These license costs will be amortized over the expected remaining lives of the respective patents. As of March 31, 2015, amortization expense for the next five years is expected to be as follows:
	2015 (remaining nine months)	$	96
	2016		128
	2017		128
	2018		128
	2019		128
	thereafter		857
	Total	$	1,465

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Sponsored Research Agreements Future Minimum Payments [Table Text Block]	We entered into a number of sponsored research agreements during 2014, primarily, which require us to make future payments as follows:
	2015 (remaining)	$	239
	2016		150
	Total	$	389

STOCK_OPTION_PLANS_Tables

STOCK OPTION PLANS (Tables)	3 Months Ended
	Mar. 31, 2015
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Stock-based compensation expense for all plans is classified in the statements of operations as follows:
		Three Months Ended March 31,
		2015			2014
	Research and development	$	184		$	78
	General and administrative		304			124
	Total	$	488		$	202
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of the Company’s stock-based awards during the three months ended March 31, 2015 and 2014 were estimated using the Black-Scholes option-pricing model with the following assumptions:
			Three Months Ended March 31,
			2015			2014
	Weighted-average volatility		262	%		89.2	%
	Weighted-average expected term		9.98			5
	Expected dividends		0	%		0	%
	Risk-free investment rate		1.65	%		1.65	%
Stock Plan 2008 [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table is a summary of activity under the 2008 Plan:
		Common Stock Options Outstanding			Weighted Average Exercise Price			Weighted Average Remaining Contractual		Aggregate Intrinsic Value
								Term  (Years)		$0
	Balance December 31, 2014		21,596,127		$	0.08			8.8	$	47
	Options granted (weighted-average fair value of $0.08)
	Employee (1)		—			—			—
	Non-employee		—			—			—
	Options cancelled		-1,500,000			0.1			—
	Options exercised		—			—			—
	Balance March 31, 2015		20,096,127		$	0.08			8.6	$	17
	Options vested as of March 31, 2015		15,035,635
Stock Plan 2014 [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table is a summary of activity under the 2014 Plan:
		Common Stock			Weighted Average Exercise Price			Weighted Average Remaining
		Options						Contractual Term  (years)
		Outstanding
	Balance – December 31, 2014		8,600,000		$	0.09			9.8
	Options granted (weighted-average fair value of $0.08)
	Employee		24,970,000			0.08			9.1
	Non-Employee		2,250,000			0.08			0.8
	Options cancelled		—			—			—
	Options Exercised		—			—			—
	Balance March 31, 2015		35,820,000		$	0.08			9.7
	Options vested as of March 31, 2015		4,816,181
Preferred Stock Plan 2012 [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	The following table is a summary of activity under the Preferred Stock Plan:
		Preferred Stock			Weighted Average			Weighted		Aggregate
		Options			Exercise Price			Average		Intrinsic
		Outstanding						Remaining		Value
								Contractual		$0
								Term
								(Years)
	Balance – December 31, 2014		2,487,500		$	0.61			8.1	$	6,836
	Preferred options cancelled		—			—			—
	Preferred options granted (weighted-average fair value of $1.61)
	Employee		—			—			—
	Non-Employee		—			—			—
	Balance – March 31, 2015		2,487,500		$	0.61			7.6	$	4,714
	Preferred options vested as of March 31, 2015		2,154,036

LIQUIDITY_AND_GOING_CONCERN_De

LIQUIDITY AND GOING CONCERN (Details Textual) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014	Mar. 31, 2014	Dec. 31, 2013
Liquidity And Going Concern [Line Items]
Cash and cash equivalents	$109	$214	$3,765	$1,033
Stock Purchase Agreement [Member]
Liquidity And Going Concern [Line Items]
Cash and cash equivalents	109
Series G Preferred Stock [Member] | Stock Purchase Agreement [Member] | Cayman Islands [Member]
Liquidity And Going Concern [Line Items]
Stock Issued During Period, Shares, New Issues	1,087
Stock Issued During Period, Value, New Issues	$5,000
Original Issue Discount Percentage	8.00%

ACQUISITION_Details

ACQUISITION (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Business Acquisition [Line Items]
Total other (expenses)	($42)	($3,906)
Net loss	-6,580	-5,542
Basic and diluted net loss per common share (in dollars per share)	($0.01)	($0.01)
Basic and diluted weighted average common shares outstanding (in shares)	1,084,768,816	630,720,618
DioGenix, Inc [Member]
Business Acquisition [Line Items]
Net Sales		0
Operating Expenses		2,229
Loss from operations		-2,229
Total other (expenses)		-4,023
Net loss	$6,580	($6,252)
Basic and diluted net loss per common share (in dollars per share)		($0.01)
Basic and diluted weighted average common shares outstanding (in shares)		630,720,618

ACQUISITION_Details_Textual

ACQUISITION (Details Textual) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross	$900	$0
Business Combination, Acquisition Related Costs	169
Net Income (Loss) Attributable to Parent, Total	-6,580	-5,542
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	8,867
DioGenix, Inc [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	99,378,881
Business Acquisition, Share Price	$0.08
Payments to Acquire Businesses, Gross	900
Business Acquisition Contingent Payment In Cash	2,000
Business Acquisition Discount Rate Assumed	30.40%
Net Income (Loss) Attributable to Parent, Total	6,580	-6,252
Payments to Acquire Businesses, Net of Cash Acquired	$8,850

NET_LOSS_PER_SHARE_Details

NET LOSS PER SHARE (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015		Mar. 31, 2014
Numerator
Net loss	($6,580)		($5,542)
Preferred stock dividends	828		26
Net loss applicable to common stockholders	($7,408)		($5,568)
Denominator
Common stock - basic (in shares)	959,737,290		630,720,618
Common shares equivalents (in shares)	125,031,526	[1]	0	[1]
Weighted average shares outstanding during the period: (in shares)	1,084,768,816		630,720,618
Net loss per share (in dollars per share)	($0.01)		($0.01)
Potentially dilutive securities:
Outstanding common stock options	56,916,000	[2]	18,296,000	[2]
Outstanding preferred stock options	2,488,000	[2]	2,488,000	[2]
Warrants	45,861,000	[2]	69,553,000	[2]
Related party liabilities	5,070,000	[2]	3,214,000	[2]
Convertible promissory note(s)	0	[2]	5,655,000	[2]
Convertible preferred stock	750,000	[2]	750,000	[2]
8% Senior Convertible Debentures [Member]
Potentially dilutive securities:
Convertible promissory note(s)	0		8,776,000
[1]	Preferred Stock Series D and E are participating securities; therefore we utilize the two class method of computing net loss per share.
[2]	The impact of stock options, warrants, convertible debt instruments and convertible preferred stock that does not have participation rights is anti-dilutive in a period of loss from continuing operations.

NET_LOSS_PER_SHARE_Details_Tex

NET LOSS PER SHARE (Details Textual)	Mar. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Intangible assets consist of:
Total licenses net	$1,465
Total intangible assets	10,277	1,497
License [Member]
Intangible assets consist of:
Licenses	1,685	1,685
Accumulated amortization of licenses	-220	-188
Total licenses net	1,465	1,497
Acquisition Diogenix (Preliminary IPRD) [Member]
Intangible assets consist of:
Total licenses net	$8,812	$0

INTANGIBLE_ASSETS_Details_1

INTANGIBLE ASSETS (Details 1) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]
2015 (remaining nine months)	$96
2016	128
2017	128
2018	128
2019	128
thereafter	857
Total	$1,465

DEMAND_PROMISSORY_NOTE_Details

DEMAND PROMISSORY NOTE (Details Textual) (USD $)	1 Months Ended	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Feb. 23, 2015	Mar. 31, 2015	Dec. 31, 2014
Demand Promissory Notes [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		8.00%	8.00%
February Note [Member]
Demand Promissory Notes [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Debt Instrument, Face Amount	$2,500
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum	24.00%
Debt Instrument, Payment Terms		At any time upon ten (10) days written notice to Dominion Capital, the Company may prepay any portion of the principal amount of the February Note and any accrued and unpaid interest at an amount equal to 110% of the then outstanding principal amount of the February Note and guaranteed interest, 10% of which may be paid in cash or, at the Company’s option, in common stock or a combination thereof.
Debt Instrument, Maturity Date	23-Dec-15
Dominion Capital, LLC. [Member] | February Note [Member]
Demand Promissory Notes [Line Items]
Debt Instrument, Face Amount		350
Debt Conversion, Converted Instrument, Shares Issued		1,250,000
Debt Conversion, Converted Instrument, Amount		102

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Mar. 31, 2015
In Thousands, unless otherwise specified
2015 (remaining)	$239
2016	150
Total	$389

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)	0 Months Ended		1 Months Ended	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Oct. 06, 2014	Aug. 31, 2014	Mar. 31, 2015
Gerald E. Commissiong [Member]
Loss Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense		$225
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage		35.00%
Deferred Compensation Arrangement with Individual, Distributions Paid		50
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	3,500,000		-5,000,000
Deferred Compensation Arrangement with Individual, Description		Mr. Commissiongs employment with the Company will be at will. Should Mr. Commissiongs employment with the Company be terminated by the Company for a reason other than for Cause (as defined in the Employment Letter) or Mr. Commissiong terminates his employment with the Company for Good Reason (as defined in the Employment Letter), Mr. Commissiong shall, upon execution of a release agreement with the Company, be entitled to receive as severance: (i) one year of his then Base Salary to be paid in the form of monthly salary continuation, (ii) one year of continued coverage under the Companys health care benefit package, (iii) a full performance bonus equal to 35% of his then Base Salary, and (iv) immediate acceleration of 25% of all outstanding unvested equity awards then held by Mr. Commissiong.
Gerald E. Commissiong [Member] | Scenario, Forecast [Member]
Loss Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense		338
John W. Commissiong, PhD [Member]
Loss Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense	175
Deferred Compensation Arrangement with Individual, Cash Awards Granted, Percentage	30.00%
Deferred Compensation Arrangement with Individual, Distributions Paid	10
John W. Commissiong, PhD [Member] | Scenario, Forecast [Member]
Loss Contingencies [Line Items]
Deferred Compensation Arrangement with Individual, Compensation Expense	266
Lonza Walkerville [Member]
Loss Contingencies [Line Items]
Business Combination Consideration Transferred Description				the Company paid $350 to Lonza on March 31, 2015 and will pay the following additional amounts to Lonza until the earlier of such time as the Option is exercised or August 31, 2015: $400 on April 30, 2015 for the option period of April 1, 2015 to April 30, 2015, $600 on May 31, 2015 for the option period of May 1, 2015 to May 31, 2015, $600 on June 30, 2015 for the option period of June 1, 2015 to June 30, 2015 and $600 on July 31, 2015 for the option period of July 1, 2015 to July 31 2015
Option Agreement Break Up Fee				1,000
Regenecin [Member] | Asset Purchase Agreement [Member]
Loss Contingencies [Line Items]
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Shares Issued				37,500,000
Remaining Payments Paid				2,500
Other Significant Noncash Transaction, Value of Consideration Received				3,600
Stock Issued During Period, Value, New Issues				3,000
Payments of Stock Issuance Costs				$1,100

EQUITY_Details_Textual

EQUITY (Details Textual) (USD $)	1 Months Ended	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Apr. 02, 2015	Mar. 31, 2015
Class of Stock [Line Items]
Amount of Remaining Shares To Be Issued Under Financing Arrangement		14,506
Common Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Value, New Issues		2,819
Common Stock [Member] | Commitment fee [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues		493,436
Common Stock [Member] | Lincoln Park Capital Fund, LLC [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues		38,445,801
Common Stock [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Conversion of Stock, Shares Issued		13,333,332
Stock Issued During Period, Shares, Restricted Stock Award, Gross	30,000,000
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Conversion of Stock, Shares Converted		549
Series D Preferred Stock [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Conversion of Stock, Shares Converted		400
Series D Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Conversion of Stock, Shares Issued		18,310,900
Stock Issued During Period Shares Stock Dividend		306,693
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues		3,278
Stock Issued During Period, Value, New Issues		2,950
Conversion of Stock, Shares Converted		500
Preferred Stock, Shares Authorized		7,779
Share Price		0.08
Series E Preferred Stock [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, New Issues		444
Stock Issued During Period, Value, New Issues		360
Preferred Stock, Shares Authorized	13,335
Share Price	0.05
Series E Preferred Stock [Member] | Common Stock [Member]
Class of Stock [Line Items]
Conversion of Stock, Shares Issued		6,250,000
Stock Issued During Period Shares Stock Dividend		2,375,204

STOCK_OPTION_PLANS_Details

STOCK OPTION PLANS (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
2008 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option Outstanding - Beginning Balance	21,596,127
Preferred Stock Option Outstanding - Options granted Employee	0
Preferred Stock Option Outstanding - Options granted Non-Employee	0
Common Stock Option Outstanding - Options Cancelled	-1,500,000
Common Stock Option Outstanding - Options Exercised	0
Option Outstanding - Ending Balance	20,096,127	21,596,127
Options vested as of March 31, 2015	15,035,635
Weighted Average Exercise Price - Beginning Balance	$0.08
Weighted Average Exercise Price - Options granted Employee	$0
Weighted Average Exercise Price - Options granted Non-Employee	$0
Weighted Average Exercise Price - Options cancelled	$0.10
Weighted Average Exercise Price - Exercised	$0
Weighted Average Exercise Price - Ending Balance	$0.08	$0.08
Weighted Average Remaining Contractual Term-Balance	8 years 7 months 6 days	8 years 9 months 18 days
Outstanding Options Common Weighted Average Remaining Contractual Term - Employee	0 years
Weighted Average Remaining Contractual Term - Non-Employee	0 years
Aggregate Intrinsic Value - Beginning Balance	$47
Aggregate Intrinsic Value - Ending Balance	$17	$47
2014 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option Outstanding - Beginning Balance	8,600,000
Preferred Stock Option Outstanding - Options granted Employee	24,970,000
Preferred Stock Option Outstanding - Options granted Non-Employee	2,250,000
Common Stock Option Outstanding - Options Cancelled	0
Common Stock Option Outstanding - Options Exercised	0
Option Outstanding - Ending Balance	35,820,000	8,600,000
Options vested as of March 31, 2015	4,816,181
Weighted Average Exercise Price - Beginning Balance	$0.09
Weighted Average Exercise Price - Options granted Employee	$0.08
Weighted Average Exercise Price - Options granted Non-Employee	$0.08
Weighted Average Exercise Price - Options cancelled	$0
Weighted Average Exercise Price - Exercised	$0
Weighted Average Exercise Price - Ending Balance	$0.08	$0.09
Weighted Average Remaining Contractual Term-Balance	9 years 8 months 12 days	9 years 9 months 18 days
Outstanding Options Common Weighted Average Remaining Contractual Term - Employee	9 years 1 month 6 days
Weighted Average Remaining Contractual Term - Non-Employee	9 months 18 days

STOCK_OPTION_PLANS_Details_1

STOCK OPTION PLANS (Details 1) (Preferred Stock Plan 2012 [Member], USD $)	3 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Preferred Stock Plan 2012 [Member]
Option Outstanding - Beginning Balance	2,487,500
Preferred Stock Option Outstanding - Options granted Employee	0
Preferred Stock Option Outstanding - Options granted Non-Employee	0
Preferred Stock Option Outstanding - Options Cancelled	0
Option Outstanding - Ending Balance	2,487,500	2,487,500
Preferred options vested	2,154,036
Weighted Average Exercise Price - Beginning Balance	$0.61
Weighted Average Exercise Price - Options granted Employee	$0
Weighted Average Exercise Price - Options granted Non-Employee	$0
Weighted Average Exercise Price - Options cancelled	$0
Weighted Average Exercise Price - Ending Balance	$0.61	$0.61
Weighted Average Remaining Contractual Term-Balance	7 years 7 months 6 days	8 years 1 month 6 days
Weighted Average Remaining Contractual Term - Employee	0 years
Weighted Average Remaining Contractual Term - Non-Employee	0 years
Aggregate Intrinsic Value - Beginning Balance	$6,836
Aggregate Intrinsic Value - Ending Balance	$4,714	$6,836

STOCK_OPTION_PLANS_Details_2

STOCK OPTION PLANS (Details 2) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$488	$202
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	184	78
General and Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$304	$124

STOCK_OPTION_PLANS_Details_3

STOCK OPTION PLANS (Details 3)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Weighted-average volatility	262.00%	89.20%
Weighted-average expected term	9 years 11 months 23 days	5 years
Expected dividends	0.00%	0.00%
Risk-free investment rate	1.65%	1.65%

STOCK_OPTION_PLANS_Details_Tex

STOCK OPTION PLANS (Details Textual) (USD $)	3 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Aug. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$3,089
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 10 months 24 days
Percentage Of Forfeiture Rate	0.00%
Stock Plan 2008 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	46,119,832
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Stock Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		153,880,168
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (USD $)	3 Months Ended	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Apr. 23, 2015
Series E Preferred Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	3,278
Stock Issued During Period, Value, New Issues	$2,950
Subsequent Event [Member]
Subsequent Event [Line Items]
Description of Conversion Premium		If the Company elects to pay the conversion premium amount in the form of common stock the number of shares to be issued shall be calculated by using 80% of the average of the lowest 5 individual daily volume weighted average prices during the measuring period, not to exceed 100% of the lowest sales prices on the last day of such period, less $0.005 per share of common stock.. Following an Event of Default, the number of shares to be issued shall be calculated by using 65% of the average of the lowest 5 individual daily volume weighted average prices during the measuring, less $0.005 per share of common stock not to exceed 70% of the lowest sales prices on the last day of such period less $0.005 per share
Additional Shares To Be Issued To Investor		22
Subsequent Event [Member] | Series E Preferred Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	444
Stock Issued During Period, Value, New Issues	360
Subsequent Event [Member] | Series G Preferred Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues		1,087
Stock Issued During Period, Value, New Issues		5,000
Percentage Of Original Issue Discount		8.00%
Preferred Stock, Dividend Rate, Percentage		8.25%
Stock Conversion Price Per Share		0.06
Percentage of Face Value on Preferred Stock		100.00%
Percentage of Face Value on Redeem Preferred Stock		120.00%
Subsequent Event [Member] | Series G Preferred Stock [Member] | Upward [Member]
Subsequent Event [Line Items]
Dividend Rate Adjust By Basis Points		0.0025
Volume Weighted Average Price		0.045
Subsequent Event [Member] | Series G Preferred Stock [Member] | Upward [Member] | Maximum [Member]
Subsequent Event [Line Items]
Preferred Stock, Dividend Rate, Percentage		24.00%
Subsequent Event [Member] | Series G Preferred Stock [Member] | Downward [Member]
Subsequent Event [Line Items]
Dividend Rate Adjust By Basis Points		0.0025
Volume Weighted Average Price		0.08
Subsequent Event [Member] | Series G Preferred Stock [Member] | Downward [Member] | Maximum [Member]
Subsequent Event [Line Items]
Preferred Stock, Dividend Rate, Percentage		0.00%
Subsequent Event [Member] | Series G Preferred Stock [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Value, New Issues		5,000
Subsequent Event [Member] | Investor [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Value, New Issues		5,000